Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatm...
Gespeichert in:
| Veröffentlicht in: | Circulation. Cardiovascular imaging 2012-09, Vol.5 (5), p.596-603 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 603 |
|---|---|
| container_issue | 5 |
| container_start_page | 596 |
| container_title | Circulation. Cardiovascular imaging |
| container_volume | 5 |
| creator | SAWAYA, Heloisa SEBAG, Igal A MARTIN, Randolph P PICARD, Michael H GERSZTEN, Robert E HALPERN, Elkan F PASSERI, Jonathan KUTER, Irene SCHERRER-CROSBIE, Marielle PLANA, Juan Carlos JANUZZI, James L KY, Bonnie TAN, Timothy C COHEN, Victor BANCHS, Jose CARVER, Joseph R WIEGERS, Susan E |
| description | Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, taxanes, and trastuzumab.
Eighty-one women with newly diagnosed human epidermal growth factor receptor 2-positive breast cancer, treated with anthracyclines followed by taxanes and trastuzumab were enrolled to be evaluated every 3 months during their cancer therapy (total of 15 months) using echocardiograms and blood samples. Left ventricular ejection fraction, peak systolic longitudinal, radial, and circumferential myocardial strain were calculated. Ultrasensitive troponin I, N-terminal pro-B-type natriuretic peptide, and the interleukin family member (ST2) were also measured. Left ventricular ejection fraction decreased (64 ± 5% to 59 ± 6%; P |
| doi_str_mv | 10.1161/CIRCIMAGING.112.973321 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3703313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22744937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-82ff8056b53eb9cc447ed1a55afaa01ff49e25f38a377b4cecced72b4a12e2533</originalsourceid><addsrcrecordid>eNpVkd1uEzEQhS1ERUvhFSrfcMcW_-169wYprEKI1JYKBXG5mvXaXUNiR7ZTJbwL74qTlNJeeTRzvjNjHYQuKLmktKIf2vm3dn49mc1vZrnBLhvJOaMv0BltBCsIqcnLQ02LpirpKXod409CKk7K-hU6ZUwK0XB5hv5MYtQxrrRL2Bs8VaNXEAbr7wKsxx0GN-BP1q8g_NIhYuMDTqPG023SbtADvg16sCpZ7_Z4e0CT31pl0w5bh28h2ewd8SJoSBn4YdOIJy6NAdROLa3T8T1ewBYOxX7dIkBMm9-bFfRv0ImBZdRvH95z9P3zdNF-Ka6-zubt5KpQopGpqJkxNSmrvuS6b5QSQuqBQlmCASDUGNFoVhpeA5eyF0orpQfJegGU5QHn5-jj0Xe96Vd6UPniAMtuHWz--K7zYLvnE2fH7s7fd1wSzuneoDoaqOBjDNo8spR0-8C6J4HlBuuOgWXw4unmR-xfQlnw7kEAUcHSBHDKxv-6SnAi6pr_BZkqpZw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>SAWAYA, Heloisa ; SEBAG, Igal A ; MARTIN, Randolph P ; PICARD, Michael H ; GERSZTEN, Robert E ; HALPERN, Elkan F ; PASSERI, Jonathan ; KUTER, Irene ; SCHERRER-CROSBIE, Marielle ; PLANA, Juan Carlos ; JANUZZI, James L ; KY, Bonnie ; TAN, Timothy C ; COHEN, Victor ; BANCHS, Jose ; CARVER, Joseph R ; WIEGERS, Susan E</creator><creatorcontrib>SAWAYA, Heloisa ; SEBAG, Igal A ; MARTIN, Randolph P ; PICARD, Michael H ; GERSZTEN, Robert E ; HALPERN, Elkan F ; PASSERI, Jonathan ; KUTER, Irene ; SCHERRER-CROSBIE, Marielle ; PLANA, Juan Carlos ; JANUZZI, James L ; KY, Bonnie ; TAN, Timothy C ; COHEN, Victor ; BANCHS, Jose ; CARVER, Joseph R ; WIEGERS, Susan E</creatorcontrib><description>Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, taxanes, and trastuzumab.
Eighty-one women with newly diagnosed human epidermal growth factor receptor 2-positive breast cancer, treated with anthracyclines followed by taxanes and trastuzumab were enrolled to be evaluated every 3 months during their cancer therapy (total of 15 months) using echocardiograms and blood samples. Left ventricular ejection fraction, peak systolic longitudinal, radial, and circumferential myocardial strain were calculated. Ultrasensitive troponin I, N-terminal pro-B-type natriuretic peptide, and the interleukin family member (ST2) were also measured. Left ventricular ejection fraction decreased (64 ± 5% to 59 ± 6%; P<0.0001) over 15 months. Twenty-six patients (32%, [22%-43%]) developed cardiotoxicity as defined by the Cardiac Review and Evaluation Committee Reviewing Trastuzumab; of these patients, 5 (6%, [2%-14%]) had symptoms of heart failure. Peak systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines treatment predicted the subsequent development of cardiotoxicity; no significant associations were observed for left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, and ST2. Longitudinal strain was <19% in all patients who later developed heart failure.
In patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines therapy are useful in the prediction of subsequent cardiotoxicity and may help guide treatment to avoid cardiac side-effects.</description><identifier>ISSN: 1941-9651</identifier><identifier>EISSN: 1942-0080</identifier><identifier>DOI: 10.1161/CIRCIMAGING.112.973321</identifier><identifier>PMID: 22744937</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Anthracyclines - administration & dosage ; Anthracyclines - adverse effects ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Biomarkers - blood ; Breast Neoplasms - drug therapy ; Cardiology. Vascular system ; Cardiovascular system ; Chi-Square Distribution ; Echocardiography ; Female ; Gynecology. Andrology. Obstetrics ; Heart ; Heart Diseases - blood ; Heart Diseases - chemically induced ; Heart Diseases - diagnosis ; Heart Diseases - diagnostic imaging ; Heart Diseases - physiopathology ; Heart Diseases - prevention & control ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Humans ; Interleukin-1 Receptor-Like 1 Protein ; Investigative techniques of hemodynamics ; Investigative techniques, diagnostic techniques (general aspects) ; Logistic Models ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Myocardial Contraction - drug effects ; Natriuretic Peptide, Brain - blood ; North America ; Peptide Fragments - blood ; Predictive Value of Tests ; Prospective Studies ; Receptors, Cell Surface - blood ; Risk Assessment ; Risk Factors ; Stroke Volume - drug effects ; Taxoids - administration & dosage ; Taxoids - adverse effects ; Time Factors ; Trastuzumab ; Troponin I - blood ; Tumors ; Ultrasonic investigative techniques ; Ventricular Function, Left - drug effects</subject><ispartof>Circulation. Cardiovascular imaging, 2012-09, Vol.5 (5), p.596-603</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-82ff8056b53eb9cc447ed1a55afaa01ff49e25f38a377b4cecced72b4a12e2533</citedby><cites>FETCH-LOGICAL-c497t-82ff8056b53eb9cc447ed1a55afaa01ff49e25f38a377b4cecced72b4a12e2533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26430488$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22744937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SAWAYA, Heloisa</creatorcontrib><creatorcontrib>SEBAG, Igal A</creatorcontrib><creatorcontrib>MARTIN, Randolph P</creatorcontrib><creatorcontrib>PICARD, Michael H</creatorcontrib><creatorcontrib>GERSZTEN, Robert E</creatorcontrib><creatorcontrib>HALPERN, Elkan F</creatorcontrib><creatorcontrib>PASSERI, Jonathan</creatorcontrib><creatorcontrib>KUTER, Irene</creatorcontrib><creatorcontrib>SCHERRER-CROSBIE, Marielle</creatorcontrib><creatorcontrib>PLANA, Juan Carlos</creatorcontrib><creatorcontrib>JANUZZI, James L</creatorcontrib><creatorcontrib>KY, Bonnie</creatorcontrib><creatorcontrib>TAN, Timothy C</creatorcontrib><creatorcontrib>COHEN, Victor</creatorcontrib><creatorcontrib>BANCHS, Jose</creatorcontrib><creatorcontrib>CARVER, Joseph R</creatorcontrib><creatorcontrib>WIEGERS, Susan E</creatorcontrib><title>Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab</title><title>Circulation. Cardiovascular imaging</title><addtitle>Circ Cardiovasc Imaging</addtitle><description>Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, taxanes, and trastuzumab.
Eighty-one women with newly diagnosed human epidermal growth factor receptor 2-positive breast cancer, treated with anthracyclines followed by taxanes and trastuzumab were enrolled to be evaluated every 3 months during their cancer therapy (total of 15 months) using echocardiograms and blood samples. Left ventricular ejection fraction, peak systolic longitudinal, radial, and circumferential myocardial strain were calculated. Ultrasensitive troponin I, N-terminal pro-B-type natriuretic peptide, and the interleukin family member (ST2) were also measured. Left ventricular ejection fraction decreased (64 ± 5% to 59 ± 6%; P<0.0001) over 15 months. Twenty-six patients (32%, [22%-43%]) developed cardiotoxicity as defined by the Cardiac Review and Evaluation Committee Reviewing Trastuzumab; of these patients, 5 (6%, [2%-14%]) had symptoms of heart failure. Peak systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines treatment predicted the subsequent development of cardiotoxicity; no significant associations were observed for left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, and ST2. Longitudinal strain was <19% in all patients who later developed heart failure.
In patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines therapy are useful in the prediction of subsequent cardiotoxicity and may help guide treatment to avoid cardiac side-effects.</description><subject>Adult</subject><subject>Anthracyclines - administration & dosage</subject><subject>Anthracyclines - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Chi-Square Distribution</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Heart</subject><subject>Heart Diseases - blood</subject><subject>Heart Diseases - chemically induced</subject><subject>Heart Diseases - diagnosis</subject><subject>Heart Diseases - diagnostic imaging</subject><subject>Heart Diseases - physiopathology</subject><subject>Heart Diseases - prevention & control</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Humans</subject><subject>Interleukin-1 Receptor-Like 1 Protein</subject><subject>Investigative techniques of hemodynamics</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Logistic Models</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Myocardial Contraction - drug effects</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>North America</subject><subject>Peptide Fragments - blood</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Receptors, Cell Surface - blood</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Stroke Volume - drug effects</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - adverse effects</subject><subject>Time Factors</subject><subject>Trastuzumab</subject><subject>Troponin I - blood</subject><subject>Tumors</subject><subject>Ultrasonic investigative techniques</subject><subject>Ventricular Function, Left - drug effects</subject><issn>1941-9651</issn><issn>1942-0080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkd1uEzEQhS1ERUvhFSrfcMcW_-169wYprEKI1JYKBXG5mvXaXUNiR7ZTJbwL74qTlNJeeTRzvjNjHYQuKLmktKIf2vm3dn49mc1vZrnBLhvJOaMv0BltBCsIqcnLQ02LpirpKXod409CKk7K-hU6ZUwK0XB5hv5MYtQxrrRL2Bs8VaNXEAbr7wKsxx0GN-BP1q8g_NIhYuMDTqPG023SbtADvg16sCpZ7_Z4e0CT31pl0w5bh28h2ewd8SJoSBn4YdOIJy6NAdROLa3T8T1ewBYOxX7dIkBMm9-bFfRv0ImBZdRvH95z9P3zdNF-Ka6-zubt5KpQopGpqJkxNSmrvuS6b5QSQuqBQlmCASDUGNFoVhpeA5eyF0orpQfJegGU5QHn5-jj0Xe96Vd6UPniAMtuHWz--K7zYLvnE2fH7s7fd1wSzuneoDoaqOBjDNo8spR0-8C6J4HlBuuOgWXw4unmR-xfQlnw7kEAUcHSBHDKxv-6SnAi6pr_BZkqpZw</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>SAWAYA, Heloisa</creator><creator>SEBAG, Igal A</creator><creator>MARTIN, Randolph P</creator><creator>PICARD, Michael H</creator><creator>GERSZTEN, Robert E</creator><creator>HALPERN, Elkan F</creator><creator>PASSERI, Jonathan</creator><creator>KUTER, Irene</creator><creator>SCHERRER-CROSBIE, Marielle</creator><creator>PLANA, Juan Carlos</creator><creator>JANUZZI, James L</creator><creator>KY, Bonnie</creator><creator>TAN, Timothy C</creator><creator>COHEN, Victor</creator><creator>BANCHS, Jose</creator><creator>CARVER, Joseph R</creator><creator>WIEGERS, Susan E</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20120901</creationdate><title>Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab</title><author>SAWAYA, Heloisa ; SEBAG, Igal A ; MARTIN, Randolph P ; PICARD, Michael H ; GERSZTEN, Robert E ; HALPERN, Elkan F ; PASSERI, Jonathan ; KUTER, Irene ; SCHERRER-CROSBIE, Marielle ; PLANA, Juan Carlos ; JANUZZI, James L ; KY, Bonnie ; TAN, Timothy C ; COHEN, Victor ; BANCHS, Jose ; CARVER, Joseph R ; WIEGERS, Susan E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-82ff8056b53eb9cc447ed1a55afaa01ff49e25f38a377b4cecced72b4a12e2533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Anthracyclines - administration & dosage</topic><topic>Anthracyclines - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Chi-Square Distribution</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Heart</topic><topic>Heart Diseases - blood</topic><topic>Heart Diseases - chemically induced</topic><topic>Heart Diseases - diagnosis</topic><topic>Heart Diseases - diagnostic imaging</topic><topic>Heart Diseases - physiopathology</topic><topic>Heart Diseases - prevention & control</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Humans</topic><topic>Interleukin-1 Receptor-Like 1 Protein</topic><topic>Investigative techniques of hemodynamics</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Logistic Models</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Myocardial Contraction - drug effects</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>North America</topic><topic>Peptide Fragments - blood</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Receptors, Cell Surface - blood</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Stroke Volume - drug effects</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - adverse effects</topic><topic>Time Factors</topic><topic>Trastuzumab</topic><topic>Troponin I - blood</topic><topic>Tumors</topic><topic>Ultrasonic investigative techniques</topic><topic>Ventricular Function, Left - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAWAYA, Heloisa</creatorcontrib><creatorcontrib>SEBAG, Igal A</creatorcontrib><creatorcontrib>MARTIN, Randolph P</creatorcontrib><creatorcontrib>PICARD, Michael H</creatorcontrib><creatorcontrib>GERSZTEN, Robert E</creatorcontrib><creatorcontrib>HALPERN, Elkan F</creatorcontrib><creatorcontrib>PASSERI, Jonathan</creatorcontrib><creatorcontrib>KUTER, Irene</creatorcontrib><creatorcontrib>SCHERRER-CROSBIE, Marielle</creatorcontrib><creatorcontrib>PLANA, Juan Carlos</creatorcontrib><creatorcontrib>JANUZZI, James L</creatorcontrib><creatorcontrib>KY, Bonnie</creatorcontrib><creatorcontrib>TAN, Timothy C</creatorcontrib><creatorcontrib>COHEN, Victor</creatorcontrib><creatorcontrib>BANCHS, Jose</creatorcontrib><creatorcontrib>CARVER, Joseph R</creatorcontrib><creatorcontrib>WIEGERS, Susan E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation. Cardiovascular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAWAYA, Heloisa</au><au>SEBAG, Igal A</au><au>MARTIN, Randolph P</au><au>PICARD, Michael H</au><au>GERSZTEN, Robert E</au><au>HALPERN, Elkan F</au><au>PASSERI, Jonathan</au><au>KUTER, Irene</au><au>SCHERRER-CROSBIE, Marielle</au><au>PLANA, Juan Carlos</au><au>JANUZZI, James L</au><au>KY, Bonnie</au><au>TAN, Timothy C</au><au>COHEN, Victor</au><au>BANCHS, Jose</au><au>CARVER, Joseph R</au><au>WIEGERS, Susan E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab</atitle><jtitle>Circulation. Cardiovascular imaging</jtitle><addtitle>Circ Cardiovasc Imaging</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>5</volume><issue>5</issue><spage>596</spage><epage>603</epage><pages>596-603</pages><issn>1941-9651</issn><eissn>1942-0080</eissn><abstract>Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, taxanes, and trastuzumab.
Eighty-one women with newly diagnosed human epidermal growth factor receptor 2-positive breast cancer, treated with anthracyclines followed by taxanes and trastuzumab were enrolled to be evaluated every 3 months during their cancer therapy (total of 15 months) using echocardiograms and blood samples. Left ventricular ejection fraction, peak systolic longitudinal, radial, and circumferential myocardial strain were calculated. Ultrasensitive troponin I, N-terminal pro-B-type natriuretic peptide, and the interleukin family member (ST2) were also measured. Left ventricular ejection fraction decreased (64 ± 5% to 59 ± 6%; P<0.0001) over 15 months. Twenty-six patients (32%, [22%-43%]) developed cardiotoxicity as defined by the Cardiac Review and Evaluation Committee Reviewing Trastuzumab; of these patients, 5 (6%, [2%-14%]) had symptoms of heart failure. Peak systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines treatment predicted the subsequent development of cardiotoxicity; no significant associations were observed for left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, and ST2. Longitudinal strain was <19% in all patients who later developed heart failure.
In patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines therapy are useful in the prediction of subsequent cardiotoxicity and may help guide treatment to avoid cardiac side-effects.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>22744937</pmid><doi>10.1161/CIRCIMAGING.112.973321</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-9651 |
| ispartof | Circulation. Cardiovascular imaging, 2012-09, Vol.5 (5), p.596-603 |
| issn | 1941-9651 1942-0080 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3703313 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Anthracyclines - administration & dosage Anthracyclines - adverse effects Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Biomarkers - blood Breast Neoplasms - drug therapy Cardiology. Vascular system Cardiovascular system Chi-Square Distribution Echocardiography Female Gynecology. Andrology. Obstetrics Heart Heart Diseases - blood Heart Diseases - chemically induced Heart Diseases - diagnosis Heart Diseases - diagnostic imaging Heart Diseases - physiopathology Heart Diseases - prevention & control Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Interleukin-1 Receptor-Like 1 Protein Investigative techniques of hemodynamics Investigative techniques, diagnostic techniques (general aspects) Logistic Models Mammary gland diseases Medical sciences Middle Aged Multivariate Analysis Myocardial Contraction - drug effects Natriuretic Peptide, Brain - blood North America Peptide Fragments - blood Predictive Value of Tests Prospective Studies Receptors, Cell Surface - blood Risk Assessment Risk Factors Stroke Volume - drug effects Taxoids - administration & dosage Taxoids - adverse effects Time Factors Trastuzumab Troponin I - blood Tumors Ultrasonic investigative techniques Ventricular Function, Left - drug effects |
| title | Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T05%3A59%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Echocardiography%20and%20Biomarkers%20for%20the%20Extended%20Prediction%20of%20Cardiotoxicity%20in%20Patients%20Treated%20With%20Anthracyclines,%20Taxanes,%20and%20Trastuzumab&rft.jtitle=Circulation.%20Cardiovascular%20imaging&rft.au=SAWAYA,%20Heloisa&rft.date=2012-09-01&rft.volume=5&rft.issue=5&rft.spage=596&rft.epage=603&rft.pages=596-603&rft.issn=1941-9651&rft.eissn=1942-0080&rft_id=info:doi/10.1161/CIRCIMAGING.112.973321&rft_dat=%3Cpubmed_cross%3E22744937%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22744937&rfr_iscdi=true |